Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Castle Biosciences's total debt was $10.08M at Sep 30, 2026. For fiscal 2025 it was $10.06M, up 0.3% from the year before. The highest annual figure on record is $25.12M in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.06M | +0.3% |
| FY2024 | Dec 31, 2024 | $10.02M | – |
| FY2023 | Dec 31, 2023 | $0 | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $25.12M | +2.5% |
| FY2018 | Dec 31, 2018 | $24.50M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $10.08M | +0.3% |
| Q2 FY2026 | Jun 30, 2026 | $10.08M | +0.3% |
| Q1 FY2026 | Mar 31, 2026 | $10.07M | +0.3% |
| Q4 FY2025 | Dec 31, 2025 | $10.06M | +0.3% |
| Q3 FY2025 | Sep 30, 2025 | $10.05M | +0.3% |
| Q2 FY2025 | Jun 30, 2025 | $10.04M | +0.3% |
| Q1 FY2025 | Mar 31, 2025 | $10.03M | +0.3% |
| Q4 FY2024 | Dec 31, 2024 | $10.02M | – |
| Q3 FY2024 | Sep 30, 2024 | $10.02M | – |
| Q2 FY2024 | Jun 30, 2024 | $10.01M | -55.4% |
| Q1 FY2024 | Mar 31, 2024 | $10.00M | -59.6% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $22.46M | -9.8% |
| Q2 FY2020 | Jun 30, 2020 | $24.74M | -15.0% |
| Q1 FY2020 | Mar 31, 2020 | $25.35M | +3.5% |
| Q4 FY2019 | Dec 31, 2019 | $25.12M | – |
| Q3 FY2019 | Sep 30, 2019 | $24.90M | – |
| Q2 FY2019 | Jun 30, 2019 | $29.12M | – |
| Q4 FY2018 | Dec 31, 2018 | $24.50M | – |
See a number that looks wrong?